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Abstract Thepurposeofthisarticlewastoprovideupdated
recommendationsforthediagnosisandtreatmentofrenalcell
carcinoma. Pathological conﬁrmation is mandatory before
treatment with ablative or focal therapies before any type of
systemic therapy. Renal cell cancer should be staged
according to the TNM classiﬁcation system. A laparoscopic
nephron-sparing surgery should be the approach for tumors
\4 cmiftechnicallyfeasible.Otherwise,radical(orpartialin
selected cases) nephrectomy is the treatment of choice, with
lymph node dissection only performed in patients with clini-
cally detected lymph node involvement. Some retrospective
evidence for a cytoreductive nephrectomy in the postimmu-
notherapy era suggests a beneﬁt in patients with good or
intermediate risk or for patients with a symptomatic primary
lesion. Adjuvant treatment with chemotherapy or with tar-
geted agents is not recommended and studies are ongoing
today. Patients with metastatic disease should be staged by
computedtomographyscansofthechest,abdomenandpelvis.
The efﬁcacy of sunitinib, bevacizumab plus interferon-a,a n d
pazopanib is well established in patients with good and
intermediate risk as well for temsirolimus in poor-risk
patients. These four agents are considered standard of care in
ﬁrst-line treatment. Sorafenib, axitinib and everolimus are
standard of care in second line in different settings based on
theirbeneﬁtinPFS.BesidessomebeneﬁtdescribedforIL-2in
highly selected patients in ﬁrst line, there is a promising and
emerging role for the new immunotherapeutic approaches in
metastatic renal cell carcinoma.
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Incidence and survival rates
Renal cancer is the 12th most common malignancy
worldwide (338,000 new cases diagnosed in 2012) with
6,474 new cases diagnosed in 2012 in Spain [1]. It occurs
more often in men than in woman (age-standardized ratios
for both incidence and mortality are 50 % higher in man
compared with woman). Worldwide incidence of all stages
has increased in recent years, 2 % yearly, and was
responsible for over 143,469 deaths in 2012 [2].
Risk factors
Approximately 75 % of renal cancers are diagnosed over
the age of 60, with a plateau reached around 70–75 years
of age [2].
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DOI 10.1007/s12094-014-1219-1Smoking is a well-established risk factor for renal can-
cer with a meta-analysis reporting a clear difference
between smokers and non-smokers and also a dose-
dependent risk in number of cigarettes smoked [3].
Smoking cessation for more than 10 years may reduce the
risk of RCC [4]. Obesity has also been established as a risk
factor for RCC. A meta-analysis provided evidence for an
association between body mass index and risk of RCC [5].
Several studies have demonstrated an inverse relationship
between physical activity and RCC risk. Several cohort
studies have reported an association with long-term
hypertension and risk of RCC [6].
Approximately 2–3 % of RCCs are familial or heredi-
tary [7] with a twofold increase incidence in a ﬁrst-degree
relative. Each histological subtype has a corresponding
hereditary component caused by distinct genetic alteration.
The most common hereditary syndrome for clear cell RCC
is the von Hippel–Lindau (VHL) syndrome. Hereditary
papillary RCC is associated exclusively with type 1 pap-
illary RCC and does not present with manifestations in
other organs. The familial leiomyomatosis and RCC syn-
drome have been correlated with mutations in the fumarate
hydratase gene (FH) and patients present with type 2
papillary RCC. Lastly, in the Birt–Hogg–Dube ´ (BHD)
syndrome, germ line mutations in the homonymous tumor
suppressor folliculin gene are characteristic and patients
present typically with chromophobe RCC, oncocytomas or
hybrid tumors.
Pathological diagnosis/molecular biology
More than 50 % of RCCs are currently detected inciden-
tally when imaging is being performed for some other
reasons. However, still a large number of patients with
RCC present with symptoms, such as ﬂank pain, gross
hematuria and palpable abdominal mass. This is considered
the ‘‘classical triad’’ for diagnosis, nowadays infrequently
seen together. Metastatic symptoms such as bone pain,
dyspnea, cough or paraneoplastic syndromes such as
hypercalcemia, unexplained fever, erythrocytosis or wast-
ing syndromes are occasionally seen, being this the reason
the name RCC as ‘‘the internist tumor’’.
A core biopsy can provide the conﬁrmation of
malignancy with the speciﬁc histological type with high
sensitivity and speciﬁcity. Biopsy is mandatory espe-
cially before the treatment with ablative or focal thera-
pies [3, B]. It is also mandatory in patients with
metastatic disease before starting any type of systemic
treatment [3, B]. The ﬁnal histopathological diagnosis,
classiﬁcation, grading and evaluation of prognostic fac-
tors are based on the nephrectomy specimen when
available.
Different histological subtypes with speciﬁc genetic
alterations have been identiﬁed with similar genetic alter-
ations seen in the familial forms.
Clear cell renal cell carcinoma
Clear cell RCC (ccRCC) is the most common subtype of
renal cancer, accounting for 75 % of all primary kidney
tumors. These tumors have clear cytoplasm secondary to
deposition of lipids and glycogen. Clear cell tumors are
commonly hypervascular and can show coagulative tumor
necrosis. The most characteristic feature seen in ccRCC is
the inactivation of von Hippel–Lindau (VHL) tumor sup-
pressor gene [8] reported in up to 75 %. Other commonly
observed cytogenetic alterations in ccRCC include losses at
3p (90 %) 14q, 8p and 9p and gains at 12q and 5q [9].
Inactivation of several histone-modifying genes has been
described, such as SETD2 (10–12 %), PBRM1 (40 %) and
BAP1 (10 %) with suggested prognostic implications [10].
Papillary renal cell carcinoma
Papillary RCC types occur in 10–15 % of cases. Multifocal
and synchronous bilateral cases are observed in 10 % of
papillary RCC. Two subtypes are described: papillary type
1 and type 2.
Germ line met proto-oncogene (MET) and FH altera-
tions are observed in the hereditary form of papillary 1 and
in the hereditary leiomyomatosis (type 2), respectively.
However, these genetic abnormalities are not frequently
observed in the sporadic forms. Cytogenetic alterations in
papillary RCC type 1 include gains of chromosomes 7, 8q,
12q, 16p, 17, 20 and loss of 9p. Papillary type 2 tumors
gain 8q, lose 1p and 9p [11].
There are conﬂicting data on the differences/similarities
in clinical behavior between papillary RCC type 1 and type
2. Nevertheless, the former appears to be associated with
fewer aggressive features than the latter, including a lower
stage and grade, as well as longer 5-year survival
(*89–94 % versus 55–74 %) [12].
Chromophobe renal cell carcinoma
ChromophobeRCCoccursin5 %ofcases.Thissubtypehas
a less aggressive phenotype when compared with the other
histological subtypes. Whether or not patients with chro-
mophobe RCC have a better survival outcome than those
with other histological subtypes is unclear. Chromophobe
histology is present in 30 % of renal tumors seen in the
hereditary Birt–Hogg–Dube ´ (BHD) syndrome [13]. This
disease is associated with mutations in the BHD gene whose
product is folliculin. Chromophobe tumors frequently have
copy number alterations at chromosome 1, 2, 6, 10, 13 and
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12317.Strongstainingforcellmembrane-boundKITproteinhas
consistently been shown in chromophobe RCC tumors.
Sarcomatoid transformation
Sarcomatoid transformation is present in 5 % of RCC. Sar-
comatoid components can occur in all histological subtypes
of RCC and do not in themselves represent a distinct histo-
logical entity. It has been suggested that a cutoff of 30 %
sarcomatoid features in the primary tumor may be useful in
predicting systemic sarcomatoid histology. TP53 alterations
occur in this dedifferentiation process [14].
Collecting duct renal cell carcinoma
Collecting duct RCCs account for less than 0.5 % of RCC.
These tumors arise from the medullary distal nephron or
Bellini ducts. Bellini ducts tumors are an aggressive his-
tological subtype, and most patients have metastases at
presentation. Cytogenetic abnormalities include losses at
1p, 8p, 9p and 16p and gains at 13q [15].
Other types
Other less common subtypes include renal translocation
carcinomas.
This rare entity of renal translocation carcinomas was ﬁrst
observedinchildrenandyoungadultsbuthasalsobeenreported
in adults. This tumor is characterized by the translocation of
Xp11.2,withthe gene fusionsinvolvingthe TFE3transcription
factor gene or TFEB. More than 10 additional histological
subtypes have been deﬁned which occur rarely. These include
the unclassiﬁed RCC, medullary, multilocular cystic RCC,
mucinous tubular and spindle cell carcinoma and carcinoma
associated with end-stage renal disease. The last WHO classi-
ﬁcation should be used to classify histology in RCC.
Staging of RCC: prognostic models for risk assessment
Staging of RCC
The staging of renal cell carcinoma (RCC) should be done
according to the TNM classiﬁcation system (version 2009)
[16] (Tables 1 and 2).
Evaluation of local disease
Computed tomography (CT) scan
The abdominal CT scan represents the gold standard in the
staging of RCC and must be performed with and without
intravenous [3, A] contrast and including images from the
nephrographic phase. A change in 15 or more Hounsﬁeld
units before and after the contrast administration will be
diagnostic of enhancement and suggesting malignancy.
Abdominal CT imaging will provide relevant information
for staging including: (1) degree of extension of primary
tumor; (2) involvement of vasculature; (3) regional lymph
nodes status; (4) adrenal gland and liver involvement; and
(5) morphology and function of the contralateral kidney.
Magnetic resonance imaging (MRI)
Abdominal MRI is not performed routinely in the staging
of RCC.
Table 1 AJCC TNM staging for RCC (7th ed.)
Primary tumor (T)
T0 No evidence of primary tumor
T1 Tumor\7 cm in diameter and limited to kidney
T1a Tumor B4 cm in diameter and limited to kidney
T1b Tumor B4 cm but\7 cm and limited to kidney
T2 Tumor[7 cm in diameter and limited to kidney
T2a Tumor[7 cm but\10 cm in diameter and limited to the
kidney
T2b Tumor[10 cm and limited to the kidney
T3 Tumor extends into major veins or perinephric tissues, but not
beyond Gerota’s fascia
T3a Tumor directly invades perinephric tissues, but not beyond
Gerota’s fascia
T3b Tumor grossly extends into vena cava below the diaphragm
T3c Tumor grossly extends into vena cava above diaphragm or
invades wall of vena cava
T4 Tumor invades beyond Gerota’s fascia (including contiguous
ipsilateral adrenal gland)
Regional lymph nodes (N)
a
N0 No regional lymph node metastasis
N1 Metastasis in regional lymph node (s)
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
a N classiﬁcation not affected by laterality
Table 2 Stage grouping for RCC Based on AJCC TNM stage and
survival
Stage T N M 5-year OS (%)
Stage I T1 N0 M0 81
Stage II T2 N0 M0 74
Stage III T1, T2 N1 M0 53
T3 Any N M0
Stage IV T4 Any N M0 10
Any T Any N M1
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123Indications of staging using MRI include: (1) allergy to
CT iv contrast or pregnancy; (2) indeterminate results of
CT regarding enhancement of complex renal masses; and
(3) investigation of venous involvement when poor deﬁ-
nition of inferior vena cava tumor thrombus in CT scan or
investigation of locally advanced disease. Despite a high
accuracy of both CT and MRI in RCC diagnosis, these tests
are not able to reliably distinguish oncocytoma and fat-free
angiomyolipoma from RCC [17].
Other imaging tests
Vascular imaging studies Studies such as arteriography/
venacavography will be utilized only in selected cases.
Radioisotope renography Renal function evaluation
studies should be considered when contemplating nephron-
sparing strategies or if any sign of impaired renal function
is present pre-surgery.
Positron emission tomography (PET) There is no deﬁned
role for PET in diagnosis or follow-up of RCC. It should be
considered investigational [1, B].
Evaluation of advanced disease
Chest imaging evaluation
In addition to the abdominal CT, the most accurate imaging
test for chest staging is the chest CT that should be con-
sidered at initial staging [3, A]. An alternative is the chest
X-ray [18].
Bone or brain studies
Outside a clinical trial, imaging studies of bone or brain
should be performed only in the presence of symptoms or
speciﬁc laboratory abnormalities [3, A] [19].
Risk assessment
Different variables including anatomical factors (i.e., size
of the tumor, renal capsule invasion, venous invasion,
adrenal and lymph node involvement), histological factors
(i.e., RCC subtype, tumor necrosis and Fuhrman grade) and
clinical factors (i.e., PS, cachexia, anemia, platelet count or
local symptoms) are incorporated in prognostic models
both in localized and metastatic disease. The UISS, SSIGN
and the postoperative Karakiewicz’s nomogram are the
most widely used prognostic models in localized disease
[20–22].
In the advanced setting, the MSKCC and the Heng
classiﬁcation are the two most spread prognostic models
although others have also been developed [23, 24] (see
Table 3).
While the MSKCC or Heng criteria should be routinely
utilized in the treatment decision process of the patient
with advanced RCC, the prognostic models in the localized
setting remain investigational until data of prospective
ongoing adjuvant studies are available.
Management of localized/resectable disease
Local disease
Surgery (nephrectomy) is the best approach with curative
intention for localized RCC. Different techniques can be
performed based on the extension of the resection
(nephron sparing [NSS] or radical [RN]) or the approach
(open vs. laparoscopic). For RCC tumors \4 cm, RN has
been associated with increased mortality when compared
with NSS. Therefore, RN is not recommended in this
context unless a NSS is not technically feasible [25].
These outcomes have not been replicated in RCC tumors
of 4–7 cm where partial and radical nephrectomy
achieved similar cancer-speciﬁc survival and overall sur-
vival [26].
Regarding the approach, when compared with radical
open surgery (ROS), radical laparoscopic nephrectomy
(RLN) seems to have less surgical related complications
Table 3 MSKCC or Heng risk criteria
MSKCC risk criteria (prognostic factors for poor OS)
KPS\80
Diagnosis to therapy\1 year
Anemia
Hypercalcemia
Elevated LDH
0 factors: favorable risk
1–2 factors: intermediate risk
C3 factors: poor risk
Heng risk criteria for VEGF-targeted therapy [prognostic factors for
poor overall survival (OS)]
KPS\80
Diagnosis to therapy\1 year
Anemia
Hypercalcemia
Neutrophilia
Thrombocytosis
0 factors: favorable risk
1–2 factors: intermediate risk
C3 factors: poor risk
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123although no differences in oncological outcomes have been
demonstrated. Therefore, when a radical approach is rec-
ommended, RLN should be prioritized [27].
When analyzed by stage, RCC tumors stage 1 (T1)
should be treated with a laparoscopic NSS if technically
feasible. Stage 2 (T2) tumors should be handled with RLN.
Stage III (T3, T4) tumors should be treated with open
radical nephrectomy. Neither extended lymph node dis-
section nor adrenalectomy has shown added survival ben-
eﬁt and should not be performed routinely unless there is
radiological or intraoperatory evidence of node involve-
ment [28, 29].
Active surveillance (AS) (described as an initial
watching of tumor size by successive abdominal imaging
tests with deferred intervention reserved for those tumors
that show clinical progression during follow-up) is an
acceptable option in elderly and comorbid patients with
small renal masses (\4 cm) detected incidentally as these
masses tend to have a relatively low RCC-speciﬁc mor-
tality [30].
Adjuvant treatment is not recommended in patients at
high risk of relapse. Adjuvant trials with targeted therapies
are ongoing or have completed accrual, and results are not
yet available. Neo-adjuvant approaches are investigational
and are not recommended in daily practice.
Management of advanced metastatic disease: ﬁrst-line,
second-line and therapeutic sequences––therapeutic
algorithm
Role of surgery
In the era of cytokines, cytoreductive nephrectomy before
systemic therapy was shown to provide a survival beneﬁt in
patients with good PS [I, A].
In the era of targeted therapies, we have retrospective
evidence that cytoreductive nephrectomy can be of beneﬁt
in patients with good or intermediate risk or for patients
with a symptomatic primary lesion [4, B]. Prospective
trials are ongoing.
Metastasectomy can be considered in selected patients
with solitary or limited number (B4) of lung metastases
and in solitary resectable metastases in other locations with
long metachronous disease-free interval. It can also be
considered in selected patients with stable responses to
targeted therapies [31].
First-line treatment
The efﬁcacy of sunitinib, bevacizumab plus interferon
(IFN)-a [1, A], pazopanib [1, B] and temsirolimus [1, A]
as ﬁrst-line therapy was compared with either IFN-a or
placebo in separate randomized phase III trials [32–36].
Results showed that each of these targeted agents was
superior to IFN-a in prolonging progression-free survival
or overall survival times, or both. The majority of the
patients in the sunitinib, pazopanib and bevacizumab plus
IFN-a trials were in the favorable or intermediate
MSKCC risk groups, and beneﬁts relative to IFN-a were
observed across groups. In the temsirolimus trial, all
patients were classiﬁed by similar criteria as having a
poor prognosis, which was equivalent to 74 % of patients
being classiﬁed in the MSKCC poor-risk group and 26 %
of patients being classiﬁed in the MSKCC intermediate-
risk group.
The results of these trials prompted many changes in
ﬁrst-line therapy recommendations. Although Interferon
plus bevacizumab have demonstrated similar impact than
oral agents as a ﬁrst-line therapy for metastatic RCC, oral
monotherapy with a TK inhibitor has become the ‘‘de
facto’’ standard of care in this situation.
Sunitinib has been the ﬁrst agent showing high activity
in ﬁrst line. To date, three phase III trials have compared
two different TKIs. After the phase III and the non-infe-
riority COMPARZ trials (median PFS 8.4 vs. 9.5 months
with pazopanib and sunitinib, respectively), pazopanib has
become an alternative option to sunitinib with some dif-
ferences in toxicity proﬁle, as ﬁrst-line therapy for
advanced or metastatic RCC [37]. In addition, two ran-
domized trials have recently compared sorafenib with
either tivozanib or axitinib. Tivozanib has become the ﬁrst
TKI that showed a beneﬁt in terms of PFS in a phase III
trial over another TKI, but was not approved because of its
lack of impact in survival [38]. On the other hand, axitinib
did not reach the pre-established target of the study, and the
trial was prematurely discontinued [39].
Recommendations (clear cell histology)
1. Sunitinib and pazopanib are best ﬁrst-line treatment
alternatives in metastatic RCC patients with good and
intermediate risk (level of evidence: I; grade of rec-
ommendation: A and B, respectively).
2. Bevacizumab combined with interferon is also an
option, although it has been less used in favor of more
convenient use of oral therapies (level of evidence: I;
grade of recommendation: A).
3. In patients with poor risk features, temsirolimus
constitutes the ﬁrst-line therapy (level of evidence: I;
grade of recommendation: A), although sunitinib may
also be an option for these patients (level of evidence:
II; grade of recommendation: B).
4. At this moment, ﬁrst-line treatment with immunother-
apy should not be recommended for patients with
Clin Transl Oncol (2014) 16:1043–1050 1047
123metastatic RCC (level of evidence: I; grade of
recommendation: A).
5. In highly selected ﬁt patient population, high dose IL-2
could be considered (level of evidence: I; grade of
recommendation: D).
Second-line treatment and therapeutic sequences
Based on a phase III study, the TKI sorafenib is approved for
patients with advanced RCC, in whom cytokine therapy has
failedorwasnotindicated[I,A][40].Sorafenibalmostdoubled
PFS in second-line therapy compared to placebo (2.8 vs.
5.5 months). With axitinib, a second TKI has recently become
available for the second-line therapy of patients after failure of
ﬁrst-linetherapywithsunitiniboracytokine[I,A].IntheAXIS
study[41],PFSwasincreasedby2 months(6.7vs.4.7 months)
with axitinib compared to sorafenib as reference [I, B]. More-
over, in second-line therapy, with everolimus an mTOR
inhibitor can be used to treat these patients [II, A]. In the phase
IIIRECORD-1study,thisagentwascomparedwithplaceboin
patients after failure of at least 1 anti-VEGF therapy and
increased median PFS (1.9 vs. 4.9 months) [42].
A phase III trial comparing an mTOR inhibitor, temsi-
rolimus, with a second TKI, sorafenib, following progres-
sion on ﬁrst-line sunitinib has been reported [43]. No
differences in PFS were found (4.2 vs. 3.9 months).
However, a signiﬁcant advantage in OS in favor of so-
rafenib was observed (16.6 vs. 12.2 months; p = 0.014).
The results of this study could be related to subsequent
treatments administered, but unfortunately, these data are
lacking. However, this ﬁnding and other retrospective
studies [44] give more support to the sequence TKI after
TKI. Nevertheless, mTOR inhibitors are also active after a
second TKI and could be a good alternative in patients with
severe toxicity on a previous TKI. Recently, a randomized
phase II study that compared the sequence of ﬁrst-line
sunitinib followed by second-line everolimus with the
reverse sequence showed a superiority in terms of PFS and
OS favoring the sunitinib––everolimus sequence [45],
suggesting that the order of administration of the agents is
not irrelevant.
Recommendations
1. After progression to ﬁrst-line therapy with a TKI,
sequential administration of alternative targeting
agents should be considered (level of evidence: I;
grade of recommendation: A). In this setting, both
sequences either administering a second TKI or mTOR
inhibitor are active therapeutic alternatives (level of
evidence: I, B for everolimus and I, B for axitinib).
2. Axitinib has been shown to be superior to sorafenib in
second-line treatment (level of evidence: I; grade of
recommendation: A), but sorafenib could be even
consider an active option (level of evidence: IV; grade
of recommendation: B).
3. Sequential therapy with mTOR inhibitors should be
considered in patients who progress after a second TKI
(level of evidence: III; grade of recommendation: B) or
in those patients who experienced poor tolerance to a
ﬁrst-line TKI (level of evidence: IV; grade of recom-
mendation: B).
Treatment of metastatic non-clear cell histology
Some studies suggest now that patients with non-clear cell
histology may beneﬁt from treatment with sunitinib, so-
rafenib or temsirolimus [III, B]. The recent communication
of ESPN trial (Tannir, N ASCO 2014) conﬁrms that ev-
erolimus is not considered today the ﬁrst option for therapy
and still the optimal therapy remains unclear and warrants
further study [46] (Table 4).
Response evaluation and follow-up
Response evaluation
Currently, response evaluation in patients with advanced
RCC is generally accepted to be performed every
Table 4 Treatment algorithm
Treatment
status
Setting Category I
evidence
Category II
evidence
Treatment naive
(ccRCC)
Good
intermediate
risk
Sunitinib
Bevacizumab/
Interferon
Pazopanib
Sorafenib
High dose IL-2
Poor risk Temsirolimus Sunitinib
Sorafenib
Second-line
(ccRCC)
Cytokine
refractory
Sorafenib
Pazopanib
Sunitinib
Axitinib
TKI failure Everolimus
Axitinib
Sorafenib
Prior mTor
inhibitors
Sunitinib
Non-Clear Cell
histology
Temsirolimus
Everolimus
Sunitinib
Sorafenib
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1238–12 weeks with CT chest–abdomen–pelvis as the method
of choice. Response Evaluation Criteria in Solid Tumors
(RECIST) is of limited utility in this setting but still
remains the standard. Other imaging changes such as those
integrated in the modiﬁed Choi criteria could be more
accurate in correlating with clinical outcomes when using
tyrosine kinase inhibitors. Special caution is needed when
interpreting moderate size changes with density variations
and no new lesions to avoid misinterpretation of progres-
sion in patients with advanced RCC [47, 48].
Follow-up
After deﬁnitive local treatment of RCC, there is no con-
sensus about the best follow-up protocol. The most widely
accepted approach is stratifying patients based on Fuhrman
Grade, TNM Stage, ECOG and type of local treatment, in
risk groups. Those patients considered with intermediate or
high risk of relapse should be followed more intensively (3
versus 6 months imaging). CT of the chest–abdomen and
pelvis is the imaging test of choice although no clear data
about the proper timing and/or number of test per year is
available (Table 5).
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